Recordati Competitors and Similar CompaniesClear all

Recordati's competitors and similar companies include Agios Pharmaceuticals, Pharmstandard, Turning Point Therapeutics and Debiopharm.

	Recordati Recordati Industria Chimica e Farmaceutica is a company that manufactures and commercializes pharmaceutical products.	Agios Pharmaceuticals Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism.	Pharmstandard Pharmstandard (also known as АО Фармстандарт) is a company that develops and manufactures pharmaceutical products.	Turning Point Therapeutics Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases.	Debiopharm Debiopharm is a biopharmaceutical company specializing in oncology and bacterial infections.
Founding Date	Founding Date 1926	Founding Date 2008	Founding Date 2003	Founding Date 2013	Founding Date 1979
Type	Type Public	Type Public	Type Subsidiary	Type Subsidiary	Type Private
Tags	Tags Healthcare drug development pharma therapy	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development pharma	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development oncology pharma
Locations	Locations Milan, IT HQ Campoverde, IT	Locations Cambridge, US HQ	Locations Dolgoprudny, RU HQ Kursk, RU Moscow, RU Petrovo Dalnee, RU Tomsk, RU Ufa, RU Vol'ginskii, RU	Locations San Diego, US HQ	Locations Lausanne, CH HQ Oss, NL
Employees	Employees 4,580	Employees 53611% increase	Employees 1,77814% increase	Employees 474% decrease	Employees 4771% decrease
Valuation ($)	Valuation ($) 12 b	Valuation ($) 2.7 b	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) €2.6b (FY, 2025)	Revenue (est.) $54m (FY, 2025)	Revenue (est.) ₽152.1b (FY, 2024)	Revenue (est.) $30.8m (FY, 2021)	Revenue (est.) N/A
Cost of goods	Cost of goods €607.7m (FY, 2025)	Cost of goods $6.3m (FY, 2025)	Cost of goods ₽117b (FY, 2024)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit €2b (FY, 2025)	Gross profit $47.7m (FY, 2025)	Gross profit ₽35.2b (FY, 2024)	Gross profit N/A	Gross profit N/A
Net income	Net income €443.6m (FY, 2025)	Net income ($412.8m) (FY, 2025)	Net income ₽22.7b (FY, 2024)	Net income ($236.6m) (FY, 2021)	Net income N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 144.4m	Total funding raised $ 2.1m